COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy and Safety of Intranasal Morphine for Pain After Third Molar Extraction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00390312
Recruitment Status : Completed
First Posted : October 19, 2006
Last Update Posted : January 4, 2008
Information provided by:
Javelin Pharmaceuticals

Brief Summary:
This study involves approximately 200 patients designed to evaluate the efficacy and safety of intranasal (IN) morphine 7.5 mg and 15 mg, intravenous morphine (IV) 7.5 mg, immediate release oral (PO) morphine 60 mg or placebo in patients with acute postsurgical pain following third molar extraction.

Condition or disease Intervention/treatment Phase
Post-Operative Pain Third Molar Extraction Drug: Intranasal Placebo Drug: Intranasal Morphine 15 mg Drug: Immediate Release Oral Morphine 60 mg Drug: Intravenous morphine Drug: Intranasal morphine 7.5 mg Drug: Oral placebo Drug: Intravenous placebo Phase 2

Detailed Description:
Diagnosis and Main Criteria for Inclusion: Dental outpatients undergoing the removal of 3 or more third molars (2 of which were required to be mandibular and both must be bony impacted third molars).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 225 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Single Dose Comparison of Analgesic Efficacy and Safety of Intranasal Morphine, Immediate Release Oral Morphine, Intravenous Morphine and Placebo in Postsurgical Dental Pain
Study Start Date : September 2001
Actual Primary Completion Date : November 2001
Actual Study Completion Date : November 2001

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: 4
Intravenous morphine
Drug: Intravenous morphine
Intravenous morphine 7.5 mg

Experimental: 1
Intranasal morphine 7.5 mg
Drug: Intranasal morphine 7.5 mg
Intranasal morphine 7.5 mg

Experimental: 2
Intranasal morphine 15 mg
Drug: Intranasal Morphine 15 mg
Intranasal Morphine 15 mg

Active Comparator: 3
Oral morphine 60 mg
Drug: Immediate Release Oral Morphine 60 mg
Immediate Release Oral Morphine 60 mg

Placebo Comparator: 5
Intranasal placebo
Drug: Intranasal Placebo
Intranasal placebo

Placebo Comparator: 6
Oral placebo
Drug: Oral placebo
Oral placebo

Placebo Comparator: 7
Intravenous placebo
Drug: Intravenous placebo
Intravenous placebo

Primary Outcome Measures :
  1. Total pain relief (TOTPAR) at the 0-2 hour time interval calculated as the time-weighted sum of the Pain Relief (PR) scores for the time interval 0-2 hours [ Time Frame: 2 hours ]

Secondary Outcome Measures :
  1. Other measures of pain relief [ Time Frame: Several time points ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female 18-40 years of age
  • Surgical extraction of at least three or more third molars (two must be mandibular and both must be bony impacted third molars)
  • Moderate or severe pain within 6 hours of completion of surgery

Exclusion Criteria:

  • Other oral surgical procedures during the same session except the removal of supernumerary third molars
  • Evidence of nasal congestion, nasal polyps, mucosal lesions of the nostrils, postnasal drip of any etiology or any clinically significant nasal pathology that may affect the absorption of study medication or the assessment of safety
  • Chronic respiratory insufficiency such that treatment with an opioid analgesic is contraindicated
  • Allergy to shellfish

Additional Inclusion/Exclusion Criteria May Apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00390312

Sponsors and Collaborators
Javelin Pharmaceuticals
Layout table for investigator information
Principal Investigator: Kyle Christensen, DDS Jean Brown Associates, Inc.
Layout table for additonal information
Responsible Party: Amy Cohen/Director, Clinical Operations, Javelin Pharmaceuticals Identifier: NCT00390312    
Other Study ID Numbers: MOR-001
First Posted: October 19, 2006    Key Record Dates
Last Update Posted: January 4, 2008
Last Verified: December 2007
Keywords provided by Javelin Pharmaceuticals:
Post operative pain
Third molar extraction
Dental surgery
Additional relevant MeSH terms:
Layout table for MeSH terms
Pain, Postoperative
Postoperative Complications
Pathologic Processes
Neurologic Manifestations
Signs and Symptoms
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents